Cite

HARVARD Citation

    Svenningsson, P. et al. (2020). A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Movement disorders. 35 (6), pp. 1046-1054. [Online]. 
  
Back to record